Value of BCL-2 and P53mt proteins in screening skin carcinoma caused by arseniasis.
- Author:
Changjun HU
1
;
Aihua ZHANG
;
Xiaoxin HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Arsenic Poisoning; complications; Humans; Immunohistochemistry; Mass Screening; Proto-Oncogene Proteins c-bcl-2; metabolism; Skin; chemistry; pathology; Skin Neoplasms; diagnosis; etiology; metabolism; Tumor Suppressor Protein p53; metabolism
- From: Chinese Journal of Epidemiology 2002;23(3):206-208
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo discuss the value of P53mt and BCL-2 proteins in screening skin carcinoma due to arseniasis.
METHODSP53mt and BCL-2 proteins were detected by immunohistochemical staining. chi(2) test was used to analyze the difference of positive rate between two groups. Screening value of the two biomarkers was also evaluated through the analysis of relative indexes.
RESULTSPositive percentages of P53mt and BCL-2 in carcinoma group were 88.89% and 94.44% respectively, both were higher than those of 36.0% and 66.0% in non-carcinoma group (for P53mt, P < 0.01; for BCL-2, P < 0.05). ORs of P53mt and BCL-2 were 14.22 (2.93 - 68.97) and 8.76 (1.07 - 71.51), respectively. Youden's Index and specificity of P53mt were 0.529 and 64.0%, which were much higher than those of BCL-2. Serial tests improved the value of screening with Youden's Index 0.569, but parallel test lowered it to 0.244.
CONCLUSIONSP53mt and BCL-2 were practical biomarkers to screen skin carcinoma due to arseniasis, and the former was better than the latter. The value of screening can be improved by a series of tests.
